国产电生理赛道突围成功，这家昆山企业获1.5亿元战略投资

Group 1 - Xianjian Technology announced a phased investment of 150 million RMB in Jianhu Medical Technology, acquiring a 30% stake without making it a subsidiary [1][10] - A strategic cooperation agreement was signed to jointly develop and commercialize cardiac interventional imaging platform products, with Xianjian holding exclusive rights for electrophysiological products [1][11] Group 2 - Xianjian Technology is a leading player in the domestic cardiovascular interventional medical device sector, established in 1999 and listed on the Hong Kong Stock Exchange in 2011 [2] - Jianhu Medical, founded in 2021, has developed the first open three-dimensional mapping platform based on dielectric imaging technology in China [4] Group 3 - Jianhu Medical completed a Pre-A round financing of several million RMB in September 2023, with support from local investment funds [5] - The investment from Xianjian Technology is seen as a significant step in realizing technological achievements and enhancing market presence [10] Group 4 - The electrophysiology market in China is dominated by multinational companies, with over 85% market share held by Johnson & Johnson, Abbott, and Medtronic [11] - Xianjian Technology aims to leverage this investment to expand its capabilities in the high-growth medical device market and accelerate the commercialization of innovative products [11]